These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 35695972)

  • 1. Upadacitinib Is Safe and Effective for Crohn's Disease: Real-World Data from a Tertiary Center.
    Traboulsi C; Ayoub F; Silfen A; Rodriguez TG; Rubin DT
    Dig Dis Sci; 2023 Feb; 68(2):385-388. PubMed ID: 35695972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
    Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
    J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's Disease.
    Chugh R; Braga-Neto MB; Fredrick TW; Ramos GP; Terdiman J; El-Nachef N; Loftus EV; Mahadevan U; Kane SV
    J Crohns Colitis; 2023 Apr; 17(4):504-512. PubMed ID: 36272109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review with Meta-analysis: Efficacy and Safety of Upadacitinib in Managing Moderate-to-Severe Crohn's Disease and Ulcerative Colitis.
    Niu C; Zhang J; Napel M; Boppana LKT; Anas H; Jadhav N; Dunnigan K; Okolo PI
    Clin Drug Investig; 2024 Jun; 44(6):371-385. PubMed ID: 38777970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upadacitinib in Crohn's disease.
    Dignass A; Esters P; Flauaus C
    Expert Opin Pharmacother; 2024 Mar; 25(4):359-370. PubMed ID: 38512115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience.
    Friedberg S; Choi D; Hunold T; Choi NK; Garcia NM; Picker EA; Cohen NA; Cohen RD; Dalal SR; Pekow J; Sakuraba A; Krugliak Cleveland N; Rubin DT
    Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1913-1923.e2. PubMed ID: 36898598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to Upadacitinib in Patients with Inflammatory Bowel Disease Previously Treated with Tofacitinib.
    Odah T; Karime C; Desai A; Picco MF; Kinnucan JA; Hashash JG; Farraye FA
    Dig Dis Sci; 2024 Oct; 69(10):3911-3919. PubMed ID: 39251560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinase 1 Inhibition With Upadacitinib in the Crohn's Disease Intestinal Mucosa: Analysis From the CELEST Study.
    Aguilar D; Revilla L; Garrido-Trigo A; Panés J; Lozano JJ; Planell N; Esteller M; Lacerda AP; Guay H; Butler J; Davis JW; Salas A
    Inflamm Bowel Dis; 2021 Nov; 27(12):1999-2009. PubMed ID: 34042156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of upadacitinib in the treatment of ulcerative colitis.
    Jordan AA; Higgins PD
    Immunotherapy; 2023 Jul; 15(10):713-727. PubMed ID: 37129377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upadacitinib for the treatment of moderate-to-severe Crohn's disease.
    Hanzel J; Ma C; Jairath V
    Immunotherapy; 2024 Apr; 16(6):345-357. PubMed ID: 38362641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Clinical Remission With Upadacitinib in a Pediatric Patient With Refractory Crohn's Disease.
    Collen LV
    Inflamm Bowel Dis; 2023 Jul; 29(7):1175-1176. PubMed ID: 36933200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
    Loftus EV; Panés J; Lacerda AP; Peyrin-Biroulet L; D'Haens G; Panaccione R; Reinisch W; Louis E; Chen M; Nakase H; Begun J; Boland BS; Phillips C; Mohamed MF; Liu J; Geng Z; Feng T; Dubcenco E; Colombel JF
    N Engl J Med; 2023 May; 388(21):1966-1980. PubMed ID: 37224198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients.
    Ponce-Bobadilla AV; Stodtmann S; Eckert D; Zhou W; Liu W; Mohamed MF
    Clin Pharmacokinet; 2023 Jan; 62(1):101-112. PubMed ID: 36571701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
    Sandborn WJ; Feagan BG; Loftus EV; Peyrin-Biroulet L; Van Assche G; D'Haens G; Schreiber S; Colombel JF; Lewis JD; Ghosh S; Armuzzi A; Scherl E; Herfarth H; Vitale L; Mohamed MF; Othman AA; Zhou Q; Huang B; Thakkar RB; Pangan AL; Lacerda AP; Panes J
    Gastroenterology; 2020 Jun; 158(8):2123-2138.e8. PubMed ID: 32044319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis.
    Law CCY; Kayal M; Mehandru S; Colombel JF
    Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):109-117. PubMed ID: 36681073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of upadacitinib for inflammatory bowel disease: A systematic review and meta-analysis of RCT and real-world observational studies.
    Zheng DY; Wang YN; Huang YH; Jiang M; Dai C
    Int Immunopharmacol; 2024 Jan; 126():111229. PubMed ID: 37977068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upadacitinib for Crohn's Disease and Ulcerative Colitis Treatment: Hitting the Selective JAKpot.
    Parigi TL; D'Amico F; Danese S
    Gastroenterology; 2021 Apr; 160(5):1472-1474. PubMed ID: 32311362
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn's disease.
    Faggiani I; D'Amico F; Bernardi F; Bencardino S; Allocca M; Furfaro F; Parigi TL; Zilli A; Fiorino G; Peyrin-Biroulet L; Danese S
    Expert Opin Drug Metab Toxicol; 2024 May; 20(5):297-305. PubMed ID: 38712496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upadacitinib: Mechanism of action, clinical, and translational science.
    Mohamed MF; Bhatnagar S; Parmentier JM; Nakasato P; Wung P
    Clin Transl Sci; 2024 Jan; 17(1):e13688. PubMed ID: 37984057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of JAK inhibitors in Crohn's Disease.
    Rogler G
    J Crohns Colitis; 2020 Aug; 14(Supplement_2):S746-S754. PubMed ID: 31781755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.